Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.
Choose a source to read (2)
Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.
1 additional source qualifications - review before use
The RX study boundary and the official categorical renal instruction are different types of evidence. A PK-only extraction can obscure a clinically important restriction.
Before applying: Read official section 8.7 before use. Do not convert the lowest studied CrCl into a newly invented avoidance cutoff.
Also check: WAYRILZ: limited RX PK wording versus official severe-renal avoidance
Official source
WAYRILZ - official renal restriction
Product / population
WAYRILZ - official renal restriction; selected renal passages, not a complete prescribing monograph.
Renal measure
Creatinine clearance (CrCl), mL/min; equation not specified in the selected passage. Section 8.7 uses categorical severity; no additional numeric boundary is inferred.
Renal dosing, restrictions and evidence limits
Section 8.7 advises avoiding WAYRILZ in severe renal impairment and requires no modification for mild or moderate impairment. The separate PK section covers CrCl 46-89 mL/min and states that values below 46 were not studied. Do not equate the lowest studied CrCl with the categorical severe-impairment restriction or invent a numerical threshold to bridge the two passages. No dialysis regimen is supplied here. This restriction supplements, rather than repairs, the limited RX rendering.
Source revision: Prescribing information revised August 2025. | Retrieved: 2026-09-09. Retrieval date is not the revision date.
All sources, comparison tools and evidence navigation
Source-first renal review
Evidence sources and renal implications
Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.
Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.
Find:
Enter at least two characters. Searches stay on this page and are not saved or sent.
All source summaries, original wording and provenance
Before applying a renal protocol
Check the setting. Compare whole sources.
No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.
Share a reproducible source review
Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.
Select two distinct source versions. The complete stored summaries will appear below.
Source-by-source comparison
These protocols may disagree and may apply to different settings. This view does not reconcile or endorse a patient-specific regimen.
Build a source-review outline for documentation
This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.
Choose one or two sources above or use the source checkboxes below.
Renal-context checklist: population, kidney trend and dialysis
These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.
Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.
These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.
source scope difference
WAYRILZ: limited RX PK wording versus official severe-renal avoidance
The RX study boundary and the official categorical renal instruction are different types of evidence. A PK-only extraction can obscure a clinically important restriction.
How to use this: Read official section 8.7 before use. Do not convert the lowest studied CrCl into a newly invented avoidance cutoff.
Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.
New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.
Official source
WAYRILZ - official renal restriction
WAYRILZ - official renal restriction; selected renal passages, not a complete prescribing monograph.
Method: Creatinine clearance (CrCl), mL/min; equation not specified in the selected passage. Section 8.7 uses categorical severity; no additional numeric boundary is inferred.
No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.
Compare or copy source versions
All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.
Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
DailyMed / Genzyme Corporation · WAYRILZ - official renal restriction; selected renal passages, not a complete prescribing monograph.
Renal method: Creatinine clearance (CrCl), mL/min; equation not specified in the selected passage. Section 8.7 uses categorical severity; no additional numeric boundary is inferred. Source date: Prescribing information revised August 2025. Retrieved: 2026-09-09
Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
Section 8.7 advises avoiding WAYRILZ in severe renal impairment and requires no modification for mild or moderate impairment. The separate PK section covers CrCl 46-89 mL/min and states that values below 46 were not studied. Do not equate the lowest studied CrCl with the categorical severe-impairment restriction or invent a numerical threshold to bridge the two passages. No dialysis regimen is supplied here. This restriction supplements, rather than repairs, the limited RX rendering.
RDM52-official-rilzabrutinib-wayrilz-384a1a0c39-C1 · Source locator: Sections 8.7 and 12.3: renal impairment; label title and revision.
Creatinine clearance (CrCl), mL/min; equation not specified in the selected passage. Section 8.7 uses categorical severity; no additional numeric boundary is inferred.
Source date/version
Prescribing information revised August 2025.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
GlobalRPh-hosted RX List · Rilzabrutinib - WAYRILZ tablets; selected renal passages, not a complete prescribing monograph.
Renal method: Creatinine clearance (CrCl), mL/min; equation not specified in the selected passage. Source date: Source revision date not established in selected retrieval. Retrieved: 2026-09-09
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Pharmacokinetic observation only. A drug-exposure observation is not itself a dose recommendation.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
The RX PK passage reports no clinically meaningful exposure differences at CrCl 46-89 mL/min; impairment below 46 was not studied. This observed study boundary is not a validated avoidance cutoff or dose-reduction rule. The selected RX rendering does not supply the full renal-population instruction. Read the official-label supplement, which separately advises avoidance in severe impairment and no modification in mild/moderate impairment.
Additional summaries stored on this page: 1 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.
This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.